TIDMIMM
Immupharma PLC
06 May 2014
FOR IMMEDIATE RELEASE RNS REACH* 6 MAY 2014
Dr. Sylviane Muller - Presentation Abstract from 2014 European
Lupus Conference
ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, provides a
summary of the presentation given by Dr. Slyviane Muller at the
European Lupus Conference which recently took place in Athens,
Greece.
The "European Lupus Meeting" is a major forum for all people
interested in the disease: with approximately 800 physicians of
various disciplines (internal medicine, rheumatology, nephrology,
dermatology, obstetrics and gynecology, neurology), health
professionals, regulatory agencies, pharmaceutical industry and
patient representatives.
Dr. Sylviane Muller is the Research Director at CNRS,
Strasbourg, France and the key inventor of Lupuzor, (also known
scientifically as P140). The title of the session was called "A
novel way of immunomodulation in lupus".
Her presentation focused partly on the on the highly competitive
and efficacious mode of mechanism of Lupuzor(TM) ,
ImmuPharma'spotential blockbuster drug for Lupus, a chronic
autoimmune disease. Lupuzor(TM) has received Special Protocol
Assessment and Fast Track Designation from the FDA for a Phase III
trial.
Dr. Sylviane Muller's Abstract : Summary
"In the pipeline of molecules with a potential for treating
lupus patients, the P140 peptide holds a lot of promise. P140 is a
21-mer linear peptide (sequence 131-151) derived from the
spliceosomal small nuclear ribonucleoprotein U1-70K. It contains a
phosphoserine residue at position 140. In a multicenter,
randomized, placebo-controlled phase IIb study, P140/Lupuzor was
safe and met its primary efficacy end points in lupus patients
(Zimmer et al., ARD 2013). These results confirm data generated in
MRL/lpr lupus-prone mice in which the preclinical studies were
conducted (Monneaux et al., EJI 2003; Schall et al., J Autoimmunity
2012). In this setting, as in human, P140 was shown to behave as an
immunomodulator and not as an immunosuppressant. In a step further,
our studies demonstrated that the P140 peptide mechanism of action
does involve autophagy processes. In a lupus context in which
macroautophagy is affected (Gros et al., Autophagy 2012), P140
readily binds HSPA8/HSC70 chaperone proteins (Page et al., PLoS ONE
2009) and reduces autophagic flux in MRL/lpr B cells (Page et al.,
ARD 2011). We recently showed that a selective form of autophagy,
chaperone-mediated autophagy (CMA), is a key target of P140. By
interfering with this particular pathway, P140 peptide may affect
the endogenous (auto)antigen processing and the peptide loading to
MHCII molecules, and as a consequence, induces a lower activation
of autoreactive T and B cells, and a reduction of autoantibodies
secreted by plasma cells (Muller and Wallace, Lupus 2014). Our
recent results shed light on mechanisms by which P140 can modulate
lupus disease and by which it may operate in humans affected by
this disorder that affect more than 5 million individuals in the
world."
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Dimitri Dimitriou, Chief Executive
Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Lisa Baderoon, Head of Investor
Relations +44 7721 413 496
+44 (0)20 7886
Panmure Gordon & Co 2500
Hugh Morgan, Fred Walsh
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has received the approval
from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. Most recent news confirmed
a five year GBP50m funding facility from Darwin Strategic and the
establishment of a Scientific Advisory Board to provide scientific
advice and support for Lupuzor's pivotal phase III programme.
ImmuPharma was founded and is led by a commercially focused Board
and management team with extensive experience.
www.immupharma.com
Dr. Sylviane Muller, Research Director at CNRS & Co-founder
of ImmuPharma France
Sylviane Muller is Professor at the Institute for Advanced Study
of the University of Strasbourg (USIAS), holder of the chair of
immunology and therapeutic chemistry, Distinguished class Research
Director and head of the 'Immunologie et chimie thérapeutiques'
unit of the "Centre National de la Recherche Scientifique" (CNRS),
the largest fundamental research organization in Europe. She
obtained her PhD at the University of Strasbourg. For two years,
she was a post-doctoral fellow in Freiburg (Germany) at the
Max-Planck Institute for Immunobiology. Her field of expertise
covers autoimmunity, immuno-peptides and synthetic vaccines. She
has made 23 patented discoveries and is widely published (330
publications and reviews/chapters). She was also a founder of
Neosystem, now Polypeptide-France, a leading peptide development
and manufacturing company. She is the key inventor of ImmuPharma's
Lupus lead drug candidate Lupuzor and has been working in this
field for more than ten years.
About the Euopean Lupus Meeting : 2014
The 9th Eurolupus Meeting was recently held in Athens, Greece.
This is the premier European Lupus Meeting with approximately 800
physicians of various disciplines (internal medicine, rheumatology,
nephrology, dermatology, obstetrics and gynecology, neurology),
nurses and patients.
The scientific program includes basic, translational and
clinical sessions as well as original research presented by an
international faculty of opinion leaders in lupus. In addition to
the main program, there was a program for patients coordinated by
Lupus Europe, the European lupus patient organization.
Attendees come to the meeting to be updated in the latest
developments, including the products, services and treatments
available in the marketplace. The meeting also includes satellite
symposia and other lupus-related educational and promotional
activities. www.lupus2014.org
*WHAT IS RNS REACH?
RNS Reach is an investor communication service aimed at
assisting listed and unlisted companies to deliver non-regulatory
news such as marketing messages, corporate and product information.
RNS Reach is based on the existing RNS UK-Regulatory service and
has the same levels of efficiency, control and broad
dissemination.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGGKMVRGDZM
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024